A Systematic Review of the Efficacy and Safety Experience Reported for Sorafenib in Advanced Renal Cell Carcinoma (RCC) in the Post-Approval Setting

BACKGROUND: Sorafenib was FDA approved in 2005 for treatment of renal cell carcinoma (RCC) based on the results of the pivotal phase 3 clinical trial, TARGET (Treatment Approaches in Renal Cancer Global Evaluation Trial). Since that time, numerous clinical studies have been undertaken that substanti...

Descripción completa

Detalles Bibliográficos
Autores principales: Fishman, Mayer N., Tomshine, Jin, Fulp, William J., Foreman, Pamela K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4382117/
https://www.ncbi.nlm.nih.gov/pubmed/25830512
http://dx.doi.org/10.1371/journal.pone.0120877

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4382117/
https://www.ncbi.nlm.nih.gov/pubmed/25830512
http://dx.doi.org/10.1371/journal.pone.0120877

Ejemplares similares